All posts by: Michael Zand

About Michael Zand

Researchers find way to improve immunotherapy drugs’ impact while limiting side effects – News-Medical.net

Continue reading

2017-11-09 NEWS

Researchers find way to improve immunotherapy drugs’ impact while limiting side effects
News-Medical.net
By connecting highly effective cancer immunotherapy drugs such as anti-CTLA4 (ipilimumab) and anti-PD-L1 (atezolizumab) to peptides that bind to tissues in and around tumors, a research team based at the University of Chicago found a way to improve the …

Continue reading

2017-11-09 NEWS

3.5세대 유전자 가위(CRISPR/Cpf1) 논문 분석 5 – IT NEWS(IT 뉴스) (보도자료)

3.5세대 유전자 가위(CRISPR/Cpf1) 논문 분석 5IT NEWS(IT 뉴스) (보도자료)요약: 생명과학자들은 최근 3세대를 넘어 보다 정확하고 표적에 특이적인 3.5세대 유전자 가위(CRISPR/Cpf1)를 발견하고 개발했다. 인간세포와 동식물세포의 유전자를 마음대로 교정하는데(Editing) 사용한다. 표적 DNA를 자른 후 세포 내 복구 시스템에 의해 다시&nbsp… Continue reading

2017-11-09 NEWS

Medscape

Stem Cell Gene Therapy Replaces Boy’s Entire Epidermis – Medscape
Medscape
Ex vivo gene therapy of epidermal cells from a boy with junctional epidermolysis bullosa enabled grafts to completely replace his epidermis.
Regeneration of the entire human epidermis using transgenic stem …Nature.com

all 4 news articles »

Continue reading

2017-11-09 NEWS

ABC Online

Gene therapy could cure Spinal Muscular Atrophy
ABC Online
A criticism is often levelled at pharmaceutical companies that they don’t seek to cure diseases – they only seek to find a long-term drug treatment which allows you to live with the disease. In the last week, two breakthroughs for treatment of Spinal

Continue reading

2017-11-09 NEWS

News-Medical.net

New gene therapy trial for X-linked myotubular myopathy offers hope to children
News-Medical.net
Ann & Robert H. Lurie Children’s Hospital of Chicago is one of the few centers participating in ASPIRO, an international Phase 1/2 clinical trial of a gene therapy product called AT132 for X-linked myotubular myopathy – a rare disease characterized by

and more »

Continue reading

2017-11-09 NEWS

Madison.com

This Gene Therapy Can Restore Vision, but Will It Break the Bank?
Motley Fool
Luxturna is a gene therapy to treat patients with vision loss from biallelic RPE65 mutation-associated retinal dystrophy. It’s administered by subretinal injection, and in trials, it’s been shown to restore vision in more than 90% of patients for up to
Spark gene therapy for blindness could come at steep costBioPharma Dive

all 2 news articles »